The promise of psychiatric pharmacogenomics

Biological Psychiatry

Volumn 77, Issue 1, 2015, Pages 29-35

  Hamilton, Steven P ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

CYP2C19; CYP2D6; Depression; GWAS; Pharmacogenetics; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; HLA ANTIGEN; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ACCURACY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MENTAL DISEASE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; REVIEW; SIDE EFFECT; GENETICS; HISTORY; MENTAL DISORDERS; PERSONALIZED MEDICINE; TREATMENT OUTCOME; TRENDS;

GENETIC VARIATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 84920645334     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.09.009     Document Type: Review

References (87)

1. L.A. Thomsen, A.G. Winterstein, B. Søndergaard, L.S. Haugbølle, and A. Melander Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care Ann Pharmacother 41 2007 1411 1426
2. M. Pirmohamed Pharmacogenetics of idiosyncratic adverse drug reactions J. Uetrecht, Adverse Drug Reactions 2010 Springer-Verlag Berlin 477 491
3. L. Becquemont Pharmacogenomics of adverse drug reactions: Practical applications and perspectives Pharmacogenomics 10 2009 961 969
4. S.C. Sim, M. Kacevska, and M. Ingelman-Sundberg Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects Pharmacogenomics J 13 2013 1 11
5. E.S. Collie-Duguid, S.C. Pritchard, R.H. Powrie, J.J. Sludden, D.A. Collier, T.T. Li, and H.L. McLeod The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations Pharmacogenetics 9 1999 37 42
6. M. Jurima, T. Inaba, D. Kadar, and W. Kalow Genetic polymorphism of mephenytoin p(4′)-hydroxylation: Difference between Orientals and Caucasians Br J Clin Pharmacol 19 1985 483 487
7. L. Bertilsson, Y.Q. Lou, Y.L. Du, Y. Liu, T.Y. Kuang, and X.M. Liao Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin Clin Pharmacol Ther 51 1992 388 397
8. N. Risch, and K. Merikangas The future of genetic studies of complex human diseases Science 273 1996 1516 1517
9. 1000 Genomes Project Consortium A map of human genome variation from population-scale sequencing Nature 467 2010 1061 1073
10. International HapMap Consortium A second generation human haplotype map of over 3.1 million SNPs Nature 449 2007 851 861
11. International HapMap Consortium Integrating common and rare genetic variation in diverse human populations Nature 467 2010 52 58
12. E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, and J. Baldwin Initial sequencing and analysis of the human genome Nature 409 2001 860 921
13. L.A. Hindorff, P. Sethupathy, H.A. Junkins, E.M. Ramos, J.P. Mehta, F.S. Collins, and T.A. Manolio Potential etiologic and functional implications of genome-wide association loci for human diseases and traits Proc Natl Acad Sci U S A 106 2009 9362 9367
14. F. McMahon, and T. Insel Pharmacogenomics and personalized medicine in neuropsychiatry Neuron 74 2012 773 776
15. J. Kirchheiner, K. Nickchen, M. Bauer, M.L. Wong, J. Licinio, I. Roots, and J. Brockmoller Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 2004 442 473
16. J. de Leon, S.C. Armstrong, and K.L. Cozza Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19 Psychosomatics 47 2006 75 85
17. J.K. Hicks, J.J. Swen, C.F. Thorn, K. Sangkuhl, E.D. Kharasch, and V.L. Ellingrod Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants Clin Pharmacol Ther 93 2013 402 408
18. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, and L. Ritz Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: Implications for clinical practice Am J Psychiatry 163 2006 28 40
19. C.M.B. Pare, and J.W. Mack Differentiation of two genetically specific types of depression by the response to antidepressant drugs J Med Genet 8 1971 306 309
20. L. Franchini, A. Serretti, M. Gasperini, and E. Smeraldi Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees J Psychiatr Res 32 1998 255 259
21. G. Ruaño, D. Villagra, U.S. Rahim, A. Windemuth, M. Kocherla, and B. Bower Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital Per Med 5 2008 579 587
22. G. Ruaño, B.L. Szarek, D. Villagra, K. Gorowski, M. Kocherla, and R.L. Seip Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder Biomark Med 7 2013 429 439
23. S. Chen, W.H. Chou, R.A. Blouin, Z. Mao, L.L. Humphries, and Q.C. Meek The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry Clin Pharmacol Ther 60 1996 522 534
24. W.H. Chou, F.X. Yan, L.J. de, J. Barnhill, T. Rogers, and M. Cronin Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness J Clin Psychopharmacol 20 2000 246 251
25. T. Rau, G. Wohlleben, H. Wuttke, N. Thuerauf, J. Lunkenheimer, M. Lanczik, and T. Eschenhagen Cyp2d6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study Clin Pharmacol Ther 75 2004 386 393
26. S. Mas, P. Gasso, S. Alvarez, E. Parellada, M. Bernardo, and A. Lafuente Intuitive pharmacogenetics: Spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes Pharmacogenomics J 12 2012 255 259
27. W.J. Tamminga, J. Wemer, B. Oosterhuis, B.A. de, S. Vranckx, and B.F. Drenth Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: A retrospective study Eur J Clin Pharmacol 59 2003 57 64
28. J.G. Hoop, L.W. Roberts, K.A. Green Hammond, and N.J. Cox Psychiatrists' attitudes regarding genetic testing and patient safeguards: A preliminary study Genet Test 12 2008 245 252
29. J.G. Hoop, M.I. Lapid, R.M. Paulson, and L.W. Roberts Clinical and ethical considerations in pharmacogenetic testing: Views of physicians in 3 "early adopting" departments of psychiatry J Clin Psychiatry 71 2010 745 753
30. J.R. Rundell, J.P. Staab, G. Shinozaki, D. Saad-Pendergrass, K. Moore, D. McAlpine, and D. Mrazek Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice Psychosomatics 52 2011 141 146
31. M. Ising, S. Lucae, E.B. Binder, T. Bettecken, M. Uhr, and S. Ripke A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression Arch Gen Psychiatry 66 2009 966 975
32. H.A. Garriock, J.B. Kraft, S.I. Shyn, E.J. Peters, J.S. Yokoyama, and G.D. Jenkins A genomewide association study of citalopram response in major depressive disorder Biol Psychiatry 67 2010 133 138
33. R. Uher, N. Perroud, M.Y.M. Ng, J. Hauser, N. Henigsberg, and W. Maier Genome-wide pharmacogenetics of antidepressant response in the GENDEP project Am J Psychiatry 167 2010 555 564
34. D. Sasayama, A. Hiraishi, M. Tatsumi, K. Kamijima, M. Ikeda, and W. Umene-Nakano Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder Pharmacogenomics J 13 2013 354 358
35. Y. Ji, J.M. Biernacka, S. Hebbring, Y. Chai, G.D. Jenkins, and A. Batzler Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: Genome-wide associations and functional genomics Pharmacogenomics J 13 2013 456 463
36. G. Laje, and F.J. McMahon Genome-wide association studies of antidepressant outcome: A brief review Prog Neuropsychopharmacol Biol Psychiatry 35 2011 1553 1557
37. GENDEP Investigators, MARS Investigators, and STAR∗D Investigators Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies Am J Psychiatry 170 2013 207 217
38. P.F. Sullivan, M.J. Daly, and M. O'Donovan Genetic architectures of psychiatric disorders: The emerging picture and its implications Nat Rev Genet 13 2012 537 551
39. EGAPP Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors Genet Med 9 2007 819 825
40. J.J. Swen, M. Nijenhuis, B.A. de, L. Grandia, A.H. Maitland-van der Zee, and H. Mulder Pharmacogenetics: From bench to byte - an update of guidelines Clin Pharmacol Ther 89 2011 662 673
41. E.J. Peters, S.L. Slager, J.B. Kraft, G.D. Jenkins, M.S. Reinalda, P.J. McGrath, and S.P. Hamilton Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR∗D sample PLoS One 3 2008 e1872
42. D.K. Hall-Flavin, J.G. Winner, J.D. Allen, J.J. Jordan, R.S. Nesheim, and K.A. Snyder Using a pharmacogenomic algorithm to guide the treatment of depression Transl Psychiatry 2 2012 e172
43. D.K. Hall-Flavin, J.G. Winner, J.D. Allen, J.M. Carhart, B. Proctor, and K.A. Snyder Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting Pharmacogenet Genomics 23 2013 535 548
44. J.L. McClay, D.E. Adkins, K. Aberg, S. Stroup, D.O. Perkins, and V.I. Vladimirov Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics Mol Psychiatry 16 2011 76 85
45. C. Lavedan, L. Licamele, S. Volpi, J. Hamilton, C. Heaton, and K. Mack Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study Mol Psychiatry 14 2009 804 819
46. R.H. Perlis, J.W. Smoller, M.A. Ferreira, A. McQuillin, N. Bass, and J. Lawrence A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder Am J Psychiatry 166 2009 718 725
47. M. Manchia, M. Adli, N. Akula, R. Ardau, J.M. Aubry, and L. Backlund Assessment of response to lithium maintenance treatment in bipolar disorder: A Consortium on Lithium Genetics (ConLiGen) report PLoS One 8 2013 e65636
48. G. Laje, A.S. Allen, N. Akula, H. Manji, R.A. John, and F.J. McMahon Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients Pharmacogenet Genomics 19 2009 666 674
49. A. Schosser, A.W. Butler, M. Ising, N. Perroud, R. Uher, and M.Y. Ng Genomewide association scan of suicidal thoughts and behaviour in major depression PLoS One 6 2011 e20690
50. N. Perroud, R. Uher, M.Y.M. Ng, M. Guipponi, J. Hauser, and N. Henigsberg Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project Pharmacogenomics J 12 2012 68 77
51. D.E. Adkins, K. Aberg, J.L. McClay, J. Bukszar, Z. Zhao, and P. Jia Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs Mol Psychiatry 16 2011 321 332
52. K. Åberg, D.E. Adkins, Y. Liu, J.L. McClay, J. Bukszar, and P. Jia Genome-wide association study of antipsychotic-induced QTc interval prolongation Pharmacogenomics J 12 2012 165 172
53. S. Volpi, C. Heaton, K. Mack, J.B. Hamilton, R. Lannan, and C.D. Wolfgang Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia Mol Psychiatry 14 2008 1024 1031
54. K. Åberg, D.E. Adkins, J. Bukszár, B.T. Webb, S.N. Caroff, and D.D. Miller Genomewide association study of movement-related adverse antipsychotic effects Biol Psychiatry 67 2010 279 282
55. A. Alkelai, L. Greenbaum, A. Rigbi, K. Kanyas, and B. Lerer Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients Psychopharmacology 206 2009 491 499
56. W.H. Chung, S.I. Hung, H.S. Hong, M.S. Hsih, L.C. Yang, and H.C. Ho Medical genetics: A marker for Stevens-Johnson syndrome Nature 428 2004 486
57. P. Chen, J.J. Lin, C.S. Lu, C.T. Ong, P.F. Hsieh, and C.C. Yang Carbamazepine-induced toxic effects and HLA-B∗1502 screening in Taiwan N Engl J Med 364 2011 1126 1133
58. T. Ozeki, T. Mushiroda, A. Yowang, A. Takahashi, M. Kubo, and Y. Shirakata Genome-wide association study identifies HLA-A∗3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population Hum Mol Genet 20 2011 1034 1041
59. M. McCormack, A. Alfirevic, S. Bourgeois, J.J. Farrell, D. Kasperaviciute, and M. Carrington HLA-A∗3101 and carbamazepine-induced hypersensitivity reactions in Europeans N Engl J Med 364 2011 1134 1143
60. A.K. Malhotra, C.U. Correll, N.I. Chowdhury, D.J. Muller, P.K. Gregersen, and A.T. Lee Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain Arch Gen Psychiatry 69 2012 904 912
61. C. Lubrano-Berthelier, B. Dubern, J.M. Lacorte, F. Picard, A. Shapiro, and S. Zhang Melanocortin 4 receptor mutations in a large cohort of severely obese adults: Prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating J Clin Endocrinol Metab 91 2006 1811 1818
62. C.J. Willer, E.K. Speliotes, R.J. Loos, S. Li, C.M. Lindgren, and I.M. Heid Six new loci associated with body mass index highlight a neuronal influence on body weight regulation Nat Genet 41 2009 25 34
63. E.L. Nurmi, S.L. Spilman, F. Whelan, L.L. Scahill, M.G. Aman, and C.J. McDougle Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies Transl Psychiatry 3 2013 e274
64. F. Czerwensky, S. Leucht, and W. Steimer MC4R rs489693: A clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 16 2013 2103 2109
65. N.A. Patsopoulos, E.E. Ntzani, E. Zintzaras, and J.P. Ioannidis CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis Pharmacogenet Genomics 15 2005 151 158
66. M.C. Athanasiou, M. Dettling, I. Cascorbi, I. Mosyagin, B.A. Salisbury, and K.A. Pierz Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis J Clin Psychiatry 72 2011 458 463
67. A.K. Daly Pharmacogenetics and human genetic polymorphisms Biochem J 429 2010 435 449
68. J.A. Johnson, T.E. Klein, and M.V. Relling Clinical implementation of pharmacogenetics: More than one gene at a time Clin Pharmacol Ther 93 2013 384 385
69. J.L. Kuiper, J.S. Lind, H.J. Groen, J. Roder, J. Grigorieva, and H. Roder VeriStrat has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib Br J Cancer 107 2012 1820 1825
70. J. Xuan, G. Pan, Y. Qiu, L. Yang, M. Su, and Y. Liu Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action J Proteome Res 10 2011 5433 5443
71. A. Serretti, M. Kato, and J.L. Kennedy Pharmacogenetic studies in depression: A proposal for methodologic guidelines Pharmacogenomics J 8 2008 90 100
72. J.S. March, S.G. Silva, S. Compton, M. Shapiro, R. Califf, and R. Krishnan The case for practical clinical trials in psychiatry Am J Psychiatry 162 2005 836 846
73. F.H. van der Baan, M.J. Knol, O.H. Klungel, A.C. Egberts, D.E. Grobbee, and K.C. Roes Potential of adaptive clinical trial designs in pharmacogenetic research Pharmacogenomics 13 2012 571 578
74. J. Woodcock, and L.J. Lesko Pharmacogenetics - tailoring treatment for the outliers N Engl J Med 360 2009 811 813
75. R.H. Perlis A Clinical risk stratification tool for predicting treatment resistance in major depressive disorder Biol Psychiatry 74 2013 7 14
76. J.A. Johnson Pharmacogenetics in clinical practice: How far have we come and where are we going? Pharmacogenomics 14 2013 835 843
77. A.H. Wu, N. Babic, and K.T. Yeo Implementation of pharmacogenomics into the clinical practice of therapeutics: Issues for the clinician and the laboratorian Per Med 6 2009 315 327
78. M.V. Relling, and T.E. Klein CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network Clin Pharmacol Ther 89 2011 464 467
79. R. Klitzman, W. Chung, K. Marder, A. Shanmugham, L. Chin, and M. Stark Attitudes and practices among internists concerning genetic testing J Genet Couns 22 2013 90 100
80. C.T. Finn, M.A. Wilcox, B.R. Korf, D. Blacker, S.R. Racette, P. Sklar, and J.W. Smoller Psychiatric genetics: A survey of psychiatrists' knowledge, opinions, and practice patterns J Clin Psychiatry 66 2005 821 830
81. J.S. Green, T.J. O'Brien, V.A. Chiappinelli, and A.F. Harralson Pharmacogenomics instruction in US and Canadian medical schools: Implications for personalized medicine Pharmacogenomics 11 2010 1331 1340
82. R.L. Slaughter Translation of pharmacogenetics to clinical practice: What will it take? Expert Rev Clin Pharmacol 5 2012 101 103
83. M.A. Hoffman, and M.S. Williams Electronic medical records and personalized medicine Hum Genet 130 2011 33 39
84. D.M. Roden, H. Xu, J.C. Denny, and R.A. Wilke Electronic medical records as a tool in clinical pharmacology: Opportunities and challenges Clin Pharmacol Ther 91 2012 1083 1086
85. P.H. O'Donnell, A. Bush, J. Spitz, K. Danahey, D. Saner, and S. Das The 1200 patients project: Creating a new medical model system for clinical implementation of pharmacogenomics Clin Pharmacol Ther 92 2012 446 449
86. J.K. Hicks, K.R. Crews, J.M. Hoffman, N.M. Kornegay, M.R. Wilkinson, and R. Lorier A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record Clin Pharmacol Ther 92 2012 563 566
87. J.M. Pulley, J.C. Denny, J.F. Peterson, G.R. Bernard, C.L. Vnencak-Jones, and A.H. Ramirez Operational implementation of prospective genotyping for personalized medicine: The Design of the Vanderbilt PREDICT Project Clin Pharmacol Ther 92 2012 87 95